INVESTORS

Investor Relations

Recent News
Nov 15, 2018

- SRA737 demonstrates preclinical efficacy in aggressive CCNE1-amplified and MYCN‑overexpressing high-grade serous ovarian cancer patient-derived xenograft (PDX) models - - PDX models were...

Nov 13, 2018

- Novel oral Cdc7 inhibitor, SRA141, demonstrates competitive target selectivity and robust efficacy in several cancer models - VANCOUVER, Nov. 13, 2018 /CNW/ - Sierra Oncology, Inc. (Nasdaq:...

Nov 8, 2018

- Momelotinib regulatory pathway clarity anticipated in H1 2019 - - SRA737 Monotherapy and LDG Combination trial preliminary data anticipated in H1 2019 - VANCOUVER, Nov. 8, 2018 /CNW/ - Sierra...

View all news releases

Events and Webcasts
Wednesday, November 14, 2018
12:20pm EST

Date: November 14, 2018 Time: 5:20 pm GMT Location: London UK

View all events and webcasts

Investor Enquiries

James Smith, Vice President Corporate Affairs
investors@sierraoncology.com

Sign up for investor alerts